Skin Cancer Detection Device
Detection of melanoma, basal cell carcinoma, and squamous cell carcinoma
Key Facts
About DermaSensor
DermaSensor is a commercial-stage diagnostics company offering an FDA-cleared, AI-driven device for non-invasive skin cancer detection at the point of care. Its handheld tool utilizes elastic scattering spectroscopy (ESS) and proprietary algorithms to analyze lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma, providing a risk assessment in seconds with reported 96% accuracy. The company targets primary care physicians, internists, and other non-specialists to address long dermatology wait times and improve early detection rates. DermaSensor is actively commercializing its device in the US, offering reimbursement assistance and positioning itself at the intersection of AI, diagnostics, and dermatology.
View full company profile